0. DOCID:18693 SCORE: 0.00327966653063595
DOCNO: 1511020
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Pleural Effusion, Malignant
AUTHOR: M Tattersall M
AFFILIATION: University of Sydney, New South Wales, Australia.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in oncology.
COUNTRY: UNITED STATES
TITLE: Pleural effusions.
PUBDATE: 19920801
Pleural effusions are a common development in patients with cancer. The optimal means of control are not defined, but systemic treatment is often effective in patients with drug-sensitive tumors. Local treatments advocated in the management of malignant pleural effusions differ in the means of drainage, the length of time pleural tubes are left in situ, and the type of intrapleural therapy administered. Randomized trials published in the past few months have suggested that bleomycin sulfate may be superior to tetracycline as a sclerosant and that mitoxantrone does not add to control of effusions compared with large-bore pleural tube alone placed at time of thoracoscopy.


1. DOCID:18644 SCORE: 0.00327964136732685
DOCNO: 1608614
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: enzymology
AUTHOR: I Romics I
AFFILIATION: St. Agnes Hospital, Urológiai Osztály, Bocholt.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Orvosi hetilap.
COUNTRY: HUNGARY
TITLE: [Comparison of the diagnostic value of different tumor markers in prostatic cancer patients]
PUBDATE: 19920601
The author compared the tumour markers of hundred virginell prostatic cancer patients. There were investigated the activity of prostatic acid phosphatase (SP) and its isoenzyme (SPP) by enzymatic method (PAP) as well. The concentration of prostatic specific antigen (PSA) was determined too. The sensibility of markers are growing on the row, SP, SPP, PAP, PSA. Summarising the results, the determination of PAP together with PSA seems to be not necessary. Because of the low price of SP, SPP their determinations is indicated in selected cases. Regarding of costs-benefit the author advises selected investigations in different stage and in different indications.


2. DOCID:19937 SCORE: 0.00316670597381359
DOCNO: 1744461
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: blood
QUALIFIER: blood
QUALIFIER: chemically induced
AUTHOR: Y Matsuura Y
AUTHOR: M Shinohara M
AUTHOR: M Kashimura M
AUTHOR: S Baba S
AUTHOR: H Otsuka H
AUTHOR: Y Okamura Y
AFFILIATION: Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Fukuoka.
PUBTYPE: Journal Article
JOURNALTITLE: Nippon Sanka Fujinka Gakkai zasshi.
COUNTRY: JAPAN
TITLE: [Disorder of serum electrolytes following CAP therapy]
PUBDATE: 19911201
Combination chemotherapy with Cyclophosphamide, Adriamycin and Cisplatin (CAP) is one of the most effective chemotherapies for ovarian cancer. Severe vomiting induced by this treatment may cause a disorder of the serum electrolytes. Severe hyponatremia was observed in one patient who complained of convulsions and unconsciousness. Accordingly we studied the disorder of serum electrolytes in 158 courses of CAP treatment (44 patients) during the five years from 1984 to 1988. The serum electrolytes were influenced by the amount of vomiting in this study. Consequently frequent examination of serum electrolytes is necessary during this treatment.


3. DOCID:19911 SCORE: 0.00316669162135771
DOCNO: 2022508
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: instrumentation
QUALIFIER: therapeutic use
QUALIFIER: radiotherapy
AUTHOR: K Wallner K
AUTHOR: S T Chiu-Tsao ST
AUTHOR: J Roy J
AUTHOR: M Rosenstein M
AUTHOR: H Smith H
AUTHOR: Z Fuks Z
AFFILIATION: Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
PUBTYPE: Journal Article
JOURNALTITLE: International journal of radiation oncology, biology, physics.
COUNTRY: UNITED STATES
TITLE: A new device to stabilize templates for transperineal I-125 implants.
PUBDATE: 19910501
Transperineal Iodine-125 implants of the prostate are currently being performed at Memorial Sloan-Kettering Cancer Center with CT-based treatment planning and transrectal ultrasound for verification of proper needle placement in the prostate at the time of implantation. An adjustable device, the WIPI, has been designed to stabilize the perineal template and rectal obturator during planning and implementation of the procedure. The device is simple to use and is compatible with CT scanning, transrectal ultrasound, and the Mick applicator. Its design and key functional features are described here.


4. DOCID:19120 SCORE: 0.00316071856437451
DOCNO: 1381451
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: M Hozumi M
AFFILIATION: Saitama Cancer Center Research Institute.
PUBTYPE: Journal Article
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Differentiation therapy of hematologic malignancies: principles, current status and perspectives]
PUBDATE: 19920601
There is increasing evidence that various tumor cells can be induced by differentiation inducers including biological response modifiers, synthetic chemicals and conventional anticancer drugs to differentiate terminally both in vitro and in vivo into cells with normal characteristics. The differentiated cells lose their abilities for proliferation and transplantation in animals. Furthermore, survival times of the animals inoculated with various tumors were found to prolong by administration with the differentiation inducers. These basic findings suggest that induction of terminal tumor cell differentiation is another strategy for cancer therapy: differentiation therapy of cancer. Principles, current status and perspectives of the differentiation therapy of leukemia are reviewed in this article.


5. DOCID:19742 SCORE: 0.0031044905841452
DOCNO: 1729088
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: adverse effects
QUALIFIER: chemically induced
QUALIFIER: drug therapy
QUALIFIER: blood
AUTHOR: S Hayashi S
AUTHOR: H Ogino H
AUTHOR: K Ogata K
AUTHOR: K Yagawa K
AFFILIATION: Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Chest.
COUNTRY: UNITED STATES
TITLE: Hypercoagulopathy induced by chemotherapy in a patient with lung cancer. A possible role for a factor with thrombosis-inducing activity (TIA).
PUBDATE: 19920101
We treated a patient with lung cancer in whom a hypercoagulopathy was induced acutely by chemotherapy. He received systemic chemotherapy twice and in both instances developed disseminated intravascular coagulopathy (DIC), accompanied by acute decrements of the peripheral platelet count and plasma fibrinogen, an increment of the fibrin degradation products (FDP), and bleeding tendency with the appearance of skin purpura. In each instance, the plasma thrombosis-inducing activity (TIA) appeared one to three days after chemotherapy and subsided subsequently.


6. DOCID:19715 SCORE: 0.0031044887505397
DOCNO: 2087870
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: etiology
QUALIFIER: adverse effects
AUTHOR: L Thür L
AFFILIATION: Evangelischen Krankenhaus Gesundbrunnen, Hofgeismar.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Zeitschrift für Lymphologie. Journal of lymphology.
COUNTRY: GERMANY
TITLE: [High fat diet and risk of breast cancer]
PUBDATE: 19901201
Eating habits, especially high-fat diets, is a topical subject that was also pointedly discussed by renowned authors at the international oncology convention in Hamburg this year. There is a continuing tendency for the incidence of breast cancer to be high in countries with high fat consumption. However, clinical comparative studies have not been able to definitely confirm any correlation between the two; probably because it is not possible to determine eating habits with a sufficient degree of reliability since these change during our lifetime. On the other hand, there is mounting evidence that overweight, rather than a high-fat diet as the result of consuming too many calories, presents the actual risk factor.


7. DOCID:19959 SCORE: 0.00292021331152007
DOCNO: 1622959
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Carcinoma, Squamous Cell
DESCRIPTOR: Pregnancy Complications, Neoplastic
DESCRIPTOR: Tongue Neoplasms
AUTHOR: S A Layton SA
AUTHOR: M Rintoul M
AUTHOR: B S Avery BS
AFFILIATION: Department of Oral and Maxillofacial Surgery, Middlesbrough General Hospital.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The British journal of oral & maxillofacial surgery.
COUNTRY: SCOTLAND
TITLE: Oral carcinoma in pregnancy.
PUBDATE: 19920601
Oral cancer presenting in pregnancy is a rare combination which, because of current epidemiological changes in the disease, may present more often in the future. Treatment of the condition can be very difficult. Decisions have to be made about terminating the pregnancy or finding a balance between the treatment of the mother and protecting the foetus from the effects of various treatment modalities. This may result in a compromise treatment of the disease. To illustrate the problems, we discuss a case of carcinoma of the tongue presenting in a 23-week pregnant Gravida 1 Para 0 lady, and review the literature.


8. DOCID:18697 SCORE: 0.00272020423285565
DOCNO: 2166345
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: therapy
AUTHOR: R J Gralla RJ
AFFILIATION: Ochsner Cancer Institute, New Orleans, LA 70121.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: UNITED STATES
TITLE: New directions in non-small cell lung cancer.
PUBDATE: 19900801
A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with non-resectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.


9. DOCID:18686 SCORE: 0.00272019769186164
DOCNO: 2108517
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: M Maffezzini M
AUTHOR: E Villa E
AUTHOR: L Broglia L
AUTHOR: F Francesca F
AUTHOR: P Rigatti P
AFFILIATION: Divisione di Urologia, Istituto Scientifico San Raffaele, Milano, Italy.
PUBTYPE: Journal Article
JOURNALTITLE: Tumori.
COUNTRY: ITALY
TITLE: Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer.
PUBDATE: 19900201
LH-RH analogues have come into use to suppress the synthesis of testosterone by the testes and to induce palliation in advanced prostate cancer. Twenty-one patients were treated with buserelin (Hoe 766), and 19 were evaluable. Stages of disease were D1-D2. Seventeen patients responded to treatment, 3 patients are still in partial response, and 16 underwent progression. The median time to progression was 12 months (range, 3-36), and the median follow-up time was 10 months (mean, 25.4; range, 5-48).


10. DOCID:19534 SCORE: 0.00258992440722556
DOCNO: 2235310
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: etiology
AUTHOR: J Koizumi J
AUTHOR: K Kodera K
AUTHOR: S Kaneda S
AFFILIATION: Department of Radiology, Saiseikai Central Hospital.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica.
COUNTRY: JAPAN
TITLE: [Liver abscess as a complication of TAE--risk factors and prevention]
PUBDATE: 19900601
Transcatheter hepatic arterial embolization for not only hepatocellular carcinoma but metastatic liver cancers is nowadays prevalent. Gall bladder infarction, cholangitis, peptic ulcers, pancreatitis, and aneurysm are reported as complications of it. But the liver abscess following it is rare. We reviewed three cases of liver abscesses after transcatheter hepatic arterial embolization. Biliary tract congestion and inflammation, and iatrogenic contaminations are supposed to major factors that caused liver abscesses. We think we should refrain from the embolization until biliary tract disorders are resolved and take care not to contaminate the proceeding materials in addition to mixing antibiotics with embolus.


11. DOCID:19451 SCORE: 0.00258987085064376
DOCNO: 1413180
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: diagnosis
QUALIFIER: diagnosis
QUALIFIER: diagnosis
AUTHOR: O H Momsen OH
AUTHOR: H P Graversen HP
AUTHOR: A Kruse A
AFFILIATION: Arhus Kommunehospital, Kirurgisk gastroenterologisk afdeling L.
PUBTYPE: Journal Article
JOURNALTITLE: Ugeskrift for laeger.
COUNTRY: DENMARK
TITLE: [Check-ups of colorectal neoplasms--current practice]
PUBDATE: 19920901
In order to investigate the practice for control of patients with colorectal adenomata and cancer, a questionnaire investigation was carried out in 1990-1991 among 53 Danish surgical departments. The investigation revealed great differences in the control programmes offered to these patients as regards the methods, the intensity and duration. In addition, differences were present in the control pattern for adenomata in specialist departments as compared with the remaining departments where there was a tendency to very frequent but, on the other hand, brief control. On the basis of these results, it is considered necessary that a reference programme should be prepared on this subject.


12. DOCID:19743 SCORE: 0.0025711642334358
DOCNO: 2128030
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: S Bhardwaj S
AUTHOR: J F Holland JF
AFFILIATION: Department of Neoplastic Diseases, Derald H. Ruttenberg Cancer Center, Mount Sinai Medical Center, New York.
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
JOURNALTITLE: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.
COUNTRY: NETHERLANDS
TITLE: A pilot trial of TMM (thiotepa, mitoxantrone and methotrexate) chemotherapy for metastatic breast cancer.
PUBDATE: 19901101
The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2. The major toxicities from the combination related to myelosuppression. Partial response was seen in 5 patients, ranging in duration from 1.25 to 10 months. Four out of eight patients who had received prior doxorubicin responded. The results are encouraging and warrant further study of this combination.


13. DOCID:19739 SCORE: 0.00256482645743051
DOCNO: 1320568
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Energy Intake
QUALIFIER: therapeutic use
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: L Ovesen L
AUTHOR: J Hannibal J
AUTHOR: L Allingstrup L
AFFILIATION: Department of Medicine C, Bispebjerg University Hospital, Copenhagen, Denmark.
PUBTYPE: Journal Article
JOURNALTITLE: European journal of clinical nutrition.
COUNTRY: ENGLAND
TITLE: Dietary intake in patients with small cell lung cancer: the effect of aggressive chemotherapy.
PUBDATE: 19920701
Energy and protein intake in 32 consecutive patients with small cell lung cancer was examined at initiation of cyclical chemotherapy and after 1 and 3 months. With each cycle intakes decreased in the first 2 days following chemotherapy, but were back to pretreatment levels on the third day. Eleven of the patients lost weight in the study period. Their energy and protein intakes were lower following chemotherapy compared to pretreatment intakes and to post-therapy intakes in weight-stable patients. Pretreatment intakes did not decrease over time, either in weight-losing or in weight-stable patients.


14. DOCID:19690 SCORE: 0.00256481899235473
DOCNO: 1667495
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Tumor Virus Infections
QUALIFIER: microbiology
QUALIFIER: classification
QUALIFIER: microbiology
AUTHOR: Y Guo Y
PUBTYPE: Journal Article
JOURNALTITLE: Zhonghua yi xue za zhi.
COUNTRY: CHINA
TITLE: [Type distribution of human papilloma virus (HPV) in cervical cancer]
PUBDATE: 19910601
For analysis of the relationship between HPV type and the progress of cervical cancer, we investigated the distribution of HPV genome type in 171 cases of papilloma, cervical neoplasm early cancer and invasive cancer. The results showed that Chinese Human Papilloma Virus type 16 (CHPV16) and Chinese Human Papilloma Virus non-classified type 1 (CHPVX1) have positive rates 11.5%, 4.8%, 50.0% and 48.8%, respectively. While HPV11/HPV6 decreased with developing of cervical neoplasia. Their positive rate was 76.9%, 26.8%, 10.0% and 2.4%, respectively. There was significant difference (P less than 0.01) in X2 test for trend. It was indicated that there is a strong correlation between the CHPV16/CHPVX1 and the developing of cervical cancer.